Видео ютуба по тегу Biotech M&A

Dealmakers 2026: Capital, M&A, and biotech’s next wave
Dealmakers 2026: Capital, M&A, and biotech’s next wave
Mizuho's Jared Holz on what biotech dealmaking looks like in 2026
Mizuho's Jared Holz on what biotech dealmaking looks like in 2026
BioMarin's $4.8B Amicus Acquisition: Rare Disease Biotech Strategy Explained
BioMarin's $4.8B Amicus Acquisition: Rare Disease Biotech Strategy Explained
Прогноз по сектору здравоохранения: во второй половине года активность в сфере слияний и поглощен...
Прогноз по сектору здравоохранения: во второй половине года активность в сфере слияний и поглощен...
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult
Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult
XBI เจาะลึก ETF Biotech เล็ก-กลาง | ทำกำไรจาก M&A + ดอกเบี้ยขาลงในมุมมอง VI #XBI #Biotech #ETFลงทุน
XBI เจาะลึก ETF Biotech เล็ก-กลาง | ทำกำไรจาก M&A + ดอกเบี้ยขาลงในมุมมอง VI #XBI #Biotech #ETFลงทุน
비만약 전쟁, 제약사 M&A 200% 폭증! 바이오株 대세로 급부상!
비만약 전쟁, 제약사 M&A 200% 폭증! 바이오株 대세로 급부상!
Episode 164 - November 21, 2025
Episode 164 - November 21, 2025
Ep. 7: Biotech M&A Insights
Ep. 7: Biotech M&A Insights
Pharma and Biotech Daily: Stay Informed on Industry Trends and M&A Activity!
Pharma and Biotech Daily: Stay Informed on Industry Trends and M&A Activity!
Pharma and Biotech Daily: M&A Surge and Regulatory Updates in the Industry
Pharma and Biotech Daily: M&A Surge and Regulatory Updates in the Industry
The Pharma and Biotech Daily: Beckley's Nasal Spray Success, M&A Activity Surge, and Job Opportun...
The Pharma and Biotech Daily: Beckley's Nasal Spray Success, M&A Activity Surge, and Job Opportun...
Pharma and Biotech Daily: The Latest in Cell and Gene Therapy, M&A Activity, and Regulatory Updates
Pharma and Biotech Daily: The Latest in Cell and Gene Therapy, M&A Activity, and Regulatory Updates
План выкупа биотехнологической компании | Как акции подскочили на 50–2100% в результате слияний и...
План выкупа биотехнологической компании | Как акции подскочили на 50–2100% в результате слияний и...
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
CDTX Stock Soars 105% on Merck Takeover: What Happens Next for Cidara Therapeutics Investors?
CDTX Stock Soars 105% on Merck Takeover: What Happens Next for Cidara Therapeutics Investors?
FDA Opens New Pathway, Pfizer’s $10B GLP-1 Win, and Biotech’s Return to Offense
FDA Opens New Pathway, Pfizer’s $10B GLP-1 Win, and Biotech’s Return to Offense
Suvannavejh: It has been a remarkable comeback for biotech
Suvannavejh: It has been a remarkable comeback for biotech
Monthly Roundup: Why is SMT popular, can biotech M&A continue and who thinks it’s an AI bubble?
Monthly Roundup: Why is SMT popular, can biotech M&A continue and who thinks it’s an AI bubble?
Ажиотаж вокруг поглощения Metsera (MTSR): начинается битва Pfizer против Novo против Lilly
Ажиотаж вокруг поглощения Metsera (MTSR): начинается битва Pfizer против Novo против Lilly
The Biotech Growth Trust webinar: Brightening Prospects for Biotechs
The Biotech Growth Trust webinar: Brightening Prospects for Biotechs
Billow AI: Analyze Biotech M&A Proxy Statements in Minutes | AI Copilot in Excel for CFOs
Billow AI: Analyze Biotech M&A Proxy Statements in Minutes | AI Copilot in Excel for CFOs
Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster
Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster
Cures, Catalysts & Comebacks: Inside Biotech’s Big Rebound | Jonathan Faison
Cures, Catalysts & Comebacks: Inside Biotech’s Big Rebound | Jonathan Faison